Parsey Merdad — SEC Form 4 filings
SEC reporting owner CIK 1792150. 19 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2024-02-02 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 7 filings — 227,277 shares, $20,426,609 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: sale of 88,119 shares @ $92.00 ($8,106,948) in GILEAD SCIENCES, INC., filed 2024-11-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | Chief Medical Officer | 12 | — | 13 legs · 227,277 sh · $20,426,609 | 27 |
| ARDELYX, INC. (ARDX) | Director | 3 | — | — | 5 |
| ArriVent BioPharma, Inc. (AVBP) | Director | 3 | — | — | 3 |
| Sagimet Biosciences Inc. (SGMT) | Director | 1 | — | — | 1 |
Form 4 filings — Parsey Merdad
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 13,562 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 26,455 @ $0 · Grant/award (A): 39,715 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 15,235 @ $0 | EDGAR |
| 2025-06-20 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 15,502 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 42,056 @ $0 · Grant/award (A): 64,457 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 28,346 (derivative) @ $0 | EDGAR |
| 2024-12-11 | 4 | GILEAD SCIENCES, INC. (GILD) | Option exercise (M): 3,820 · Tax withholding (F): 1,771 @ $92.34 · Option exercise (M): 3,820 (derivative) | EDGAR |
| 2024-11-29 | 4 | GILEAD SCIENCES, INC. (GILD) | Option exercise (M): 57,294 @ $57.92 · Option exercise (M): 88,119 @ $65.38 · Sale (S): 57,294 @ $91.79 · Sale (S): 88,119 @ $92 · Sale (S): 5,200 @ $91.80 · Sale (S): 3,199 @ $91.80 · +3 more | EDGAR |
| 2024-11-07 | 4 | GILEAD SCIENCES, INC. (GILD) | Option exercise (M): 25,000 @ $57.92 · Sale (S): 20,590 @ $91.50 · Sale (S): 5,000 @ $91.50 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | GILEAD SCIENCES, INC. (GILD) | Sale (S): 2,000 @ $83.83 | EDGAR |
| 2024-09-13 | 4 | GILEAD SCIENCES, INC. (GILD) | Option exercise (M): 25,000 @ $57.92 · Sale (S): 21,246 @ $84.50 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2024-09-11 | 4 | GILEAD SCIENCES, INC. (GILD) | Option exercise (M): 3,821 · Tax withholding (F): 1,766 @ $81.44 · Option exercise (M): 3,821 (derivative) | EDGAR |
| 2024-07-01 | 4 | GILEAD SCIENCES, INC. (GILD) | Sale (S): 2,000 @ $68.63 | EDGAR |
| 2024-06-11 | 4 | GILEAD SCIENCES, INC. (GILD) | Option exercise (M): 3,820 · Tax withholding (F): 1,744 @ $65.25 · Option exercise (M): 3,820 (derivative) | EDGAR |
| 2024-06-07 | 4 | Sagimet Biosciences Inc. (SGMT) | Grant/award (A): 51,459 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | GILEAD SCIENCES, INC. (GILD) | Sale (S): 2,000 @ $72.96 | EDGAR |
| 2024-03-11 | 4 | GILEAD SCIENCES, INC. (GILD) | Option exercise (M): 3,455 · Option exercise (M): 6,946 · Tax withholding (F): 4,803 @ $75.12 · Option exercise (M): 3,455 (derivative) · Option exercise (M): 6,946 (derivative) · Grant/award (A): 89,660 (derivative) @ $0 · +1 more | EDGAR |
| 2024-02-29 | 4 | GILEAD SCIENCES, INC. (GILD) | Sale (S): 2,000 @ $73.18 · Sale (S): 8,230 @ $72.74 | EDGAR |
| 2024-02-02 | 4 | GILEAD SCIENCES, INC. (GILD) | Grant/award (A): 20,229 @ $0 · Grant/award (A): 56,624 @ $0 · Tax withholding (F): 23,709 @ $78.26 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1792150 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →